Back to resultsStudy of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody
Primary Purpose
Hypertension
Status
Unknown status
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
candesartan cilexetil
Sponsored by
About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria: Hypertension (2 grade) Exclusion Criteria: Secondary hypertension Known sensitivity or intolerance to an angiotensin II receptor antagonist or ACE inhibitor Pregnancy
Sites / Locations
- Department of Cardiology, Wuhan Union HospitalRecruiting
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00360763
First Posted
August 4, 2006
Last Updated
August 4, 2006
Sponsor
Huazhong University of Science and Technology
1. Study Identification
Unique Protocol Identification Number
NCT00360763
Brief Title
Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody
Study Type
Interventional
2. Study Status
Record Verification Date
August 2006
Overall Recruitment Status
Unknown status
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2006 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Huazhong University of Science and Technology
4. Oversight
5. Study Description
Brief Summary
The autoantibodies against AT1 receptor (ATR-AA), behaving like an agonist were detected in patients with hypertension. ATR-AA which can blocked by ARB may play a role in the pathogenesis of hypertension. The present study is to explore whether AT1 receptor blocker has superior anti-hypertensive effect in patients with positive ATR-AA hypertension. Patients with 2 grade hypertension were recruited and ATR-AA was assayed by ELISA. A study was carried out and the efficacy of anti-hypertension was compared between candesartan cilexetil and ACE inhibitor imidapril.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
600 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
candesartan cilexetil
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Hypertension (2 grade)
Exclusion Criteria:
Secondary hypertension
Known sensitivity or intolerance to an angiotensin II receptor antagonist or ACE inhibitor
Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yu-Hua Liao
Organizational Affiliation
Union Hospital, Tongji Medical College
Official's Role
Study Director
Facility Information:
Facility Name
Department of Cardiology, Wuhan Union Hospital
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430022
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yu-Hua Liao, Doctor
Phone
00862785726376
Email
yumiaowei@vip.sina.com
12. IPD Sharing Statement
Citations:
PubMed Identifier
12358154
Citation
Liao YH, Wei YM, Wang M, Wang ZH, Yuan HT, Cheng LX. Autoantibodies against AT1-receptor and alpha1-adrenergic receptor in patients with hypertension. Hypertens Res. 2002 Jul;25(4):641-6. doi: 10.1291/hypres.25.641.
Results Reference
background
PubMed Identifier
21296780
Citation
Wei F, Jia XJ, Yu SQ, Gu Y, Wang L, Guo XM, Wang M, Zhu F, Cheng X, Wei YM, Zhou ZH, Fu M, Liao YH; SOT-AT1 Study Group. Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies. Heart. 2011 Mar;97(6):479-84. doi: 10.1136/hrt.2009.192104. Epub 2011 Feb 4.
Results Reference
derived
Learn more about this trial
Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody
We'll reach out to this number within 24 hrs